Tech Company Financing Transactions
Artios Pharma Funding Round
RA Capital Management, SV Health Investors and Andera Partners invested in a $115 million Series D funding round for Artios Pharma. This venture round closed on 11/17/2025.
Transaction Overview
Company Name
Announced On
11/17/2025
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to expand the clinical evaluation of its lead program, alnodesertib, to enroll additional ATM-negative patients in each of second-line pancreatic cancer and third-line colorectal cancer, for which the program was recently granted U.S. FDA Fast Track Designation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, Undisclosed
UK
Cambridge, Undisclosed
UK
Phone
Website
Email Address
Overview
Artios is leading the DNA Damage Response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of pioneering DDR drug developers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Andriole
Browse more venture capital transactions:
Prev: 11/17/2025: Reelables venture capital transaction
Next: 11/17/2025: AKA Foods venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs